Start with traceable material
We prioritize research literature, study registries, official sources, and primary documentation where available.
Independent information resource
Sankora is an independent resource on ibogaine’s pharmacology, brain effects, recovery research, and safety considerations. It distinguishes mechanistic findings, human observational evidence, and limited controlled evidence in plain language.
Why Sankora exists
Sankora exists for people seeking careful, understandable context around a complex subject. The main Sankora resource is designed to make distinctions visible: what a laboratory finding can suggest, what an observational report can describe, and what limited controlled evidence can and cannot establish.
We aim to reduce false certainty rather than manufacture it. Our purpose is to organize difficult material into a form that supports informed questions, without presenting information as personal medical, legal, or treatment guidance.
We prioritize research literature, study registries, official sources, and primary documentation where available.
Mechanistic work, human observations, and controlled studies are not treated as interchangeable.
We state uncertainty, note important limits, and avoid translating preliminary findings into promises.
Our editorial approach
Our approach is built around source traceability and scope. When available, we look to registries such as ClinicalTrials.gov to distinguish a registered study from a completed one, and we use published literature alongside official materials to identify what has actually been assessed.
We also make room for the limits of source types. A research paper, an individual account, a clinical protocol, and a commercial claim each answer different questions. Sankora’s information framework is organized to help readers notice those differences before drawing their own conclusions.
What we cover
Sankora covers the questions people commonly encounter while trying to assess claims, risks, and research. This includes the pathways described in discussions of ibogaine cost, the context behind European treatment-center information, and the reported experiences collected around ibogaine aftereffects.
We also acknowledge that readers arrive with different concerns. Some seek material about ibogaine and depression, others are evaluating claims about alcohol-related outcomes, or looking for context around PTSD treatment claims. These subjects require especially careful reading because a question of interest is not, by itself, proof of safety or effectiveness.
Where terminology needs a common reference point, the evidence-based medicine overview usefully describes the broader practice of integrating evidence with judgment and individual circumstances. Sankora does not replace that judgment or provide it.
Editorial principles
Our guiding principles are deliberately simple. They are intended to keep the resource useful when the available information is complicated, incomplete, or heavily marketed.
“Information can help frame a question. It cannot make a clinical decision for someone.”
Independent by design
Sankora is an independent information resource. It does not diagnose, recommend, screen, monitor, arrange treatment, or offer legal advice. The FDA’s drug safety information is one example of why risk information should be evaluated through appropriate medical and regulatory channels rather than through general web content alone.
Our role is to make the available information easier to inspect—not to stand in for qualified care, emergency support, or individualized professional advice.